Drug intelligence / Profile preview

CFX-1

Development stage: Preclinical
Lead developer: Akari Therapeutics
Modality: Small Molecules

Overview

CFX-1 is a product candidate developed by Celsus USA, based on technology licensed from Yissum, Research & Development Company of the Hebrew University of Jerusalem. It is a lipid conjugate designed for the treatment of various inflammatory diseases. Celsus USA holds an exclusive, worldwide license for this technology and is responsible for the development of CFX-1 and other related product candidates.

Beyond the preview

Go deeper on CFX-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CFX-1.